Figure 5From: VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Survival analysis under FLO/FLP treatment in an observation period of 5Â years. A. VEGF-R3 and CXCR4 positive. B. VEGF-R3 and CXCR4 negative.Back to article page